Adverse cardiovascular, limb, and renal outcomes in patients with diabetes after peripheral artery disease revascularization treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Table 2 Number of events, event rates, and hazard ratios (HR) for SGLT2i versus DPP4i among patients with T2D who had undergone PAD revascularization after propensity score matching

	SGLT2i		DPP4i		Cox model
	(n = 1,598)		(n = 1,598)		Cox model
	Number	Incidence rate per 100 person-year	Number	Incidence rate per 100 person-year	HR (95% CI)	P value
Cardiovascular outcomes
Ischemic stroke	58	1.87	52	1.81	1.05 (0.72–1.52)	0.8146
Acute myocardial infarction	47	1.50	48	1.67	0.81 (0.52–1.26)	0.5946
Heart failure hospitalization	85	2.76	61	2.14	1.39 (0.97–1.99)	0.1014
Cardiac death	39	1.23	62	2.12	0.60 (0.40–0.90)	0.0126
Limb outcomes
Repeated revascularization	165	5.63	177	6.67	0.86 (0.70–1.06)	0.1602
Lower limb amputation	39	1.25	46	1.60	0.81 (0.53–1.24)	0.3358
Composite renal outcomes	34	1.08	81	2.84	0.40 (0.27–0.59)	< 0.0001

CI confidence interval, DPP4i dipeptidyl peptidase-4 inhibitors, HR hazard ratio, PAD peripheral artery disease, SGLT2i sodium glucose co-transporter-2 inhibitors, T2D type-2 diabetes

ISSN: 1758-5996